We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

68 hedge funds and large institutions have $34.4M invested in Matinas BioPharma in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 5 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 5

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

6% more funds holding

Funds holding: 64 → 68 (+4)

0.22% more ownership

Funds ownership: 0.37% → 0.58% (+0.22%)

49% less capital invested

Capital invested by funds: $67.4M → $34.4M (-$33M)

Holders
68
Holders Change
+4
Holders Change %
+6.25%
% of All Funds
1.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
27
Reduced
5
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$13.6M
2
Victory Capital Management
Victory Capital Management
Texas
+$7.75M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.74M
4
BC
Boxer Capital
California
+$1.56M
5
BBA
Baker Bros. Advisors
New York
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
-$454K
2
OAM
Oxford Asset Management
United Kingdom
-$251K
3
ECM
ExodusPoint Capital Management
New York
-$180K
4
SG Americas Securities
SG Americas Securities
New York
-$101K
5
IWAG
Integer Wealth Advisors Group
Georgia
-$82K
Name Holding Trade Value Shares
Change 		Change in
Stake
SBWIC
51
Schaper Benz & Wise Investment Counsel
Wisconsin
$9K – – –
SPC
52
Sigma Planning Corp
Michigan
$7K -$1.03K -17 -7%
CFS
53
CRA Financial Services
New Jersey
$6K – – –
FAIM
54
Financial Advocates Investment Management
Washington
$6K – – –
FC
55
Fore Capital
New York
$6K – – –
Franklin Resources
56
Franklin Resources
California
$6K – – –
PA
57
Planning Alternatives
Michigan
$6K +$12.1K +200 New
TSS
58
Two Sigma Securities
New York
$6K +$13.1K +217 New
UBS Group
59
UBS Group
Switzerland
$5K +$5.62K +93 +129%
Osaic Holdings
60
Osaic Holdings
Arizona
$4K +$7.25K +120 New
AIC
61
Ameritas Investment Company
Nebraska
$3K +$6.76K +112 New
HFM
62
Hartford Financial Management
Connecticut
$2K – – –
CAL
63
Capital Analysts LLC
Pennsylvania
$1K – – –
SPIA
64
Steward Partners Investment Advisory
New York
$1K +$3.68K +61 New
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$15 – – –
CIBC Private Wealth Group
66
CIBC Private Wealth Group
Georgia
– -$454K -4,000 Closed
OAM
67
Oxford Asset Management
United Kingdom
– -$251K -2,214 Closed
IWAG
68
Integer Wealth Advisors Group
Georgia
– -$82K -1,156 Closed
Citadel Advisors
69
Citadel Advisors
Florida
– -$63K -556 Closed
WCA
70
Windsor Creek Advisors
Vermont
– -$33 -294 Closed
BFM
71
Boothbay Fund Management
New York
– -$23K -200 Closed
Citigroup
72
Citigroup
New York
– -$23K -200 Closed
EWM
73
Endurance Wealth Management
Rhode Island
– -$2K -25 Closed
TRCT
74
Tower Research Capital (TRC)
New York
– +$121 +2 New
TWA
75
TCI Wealth Advisors
Arizona
– +$242 +4 +200%
1 2
3

MTNB Hedge Fund Activity: Q1 2020 in Review

68 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2020, worth a combined $34.4M — down 49% from $67.4M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new MTNB positions and 8 closed out — a net gain of 6 holders — while 27 added to existing stakes and 5 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $13.6M. The largest seller was CIBC Private Wealth Group, exiting entirely with an estimated $454K sold.

  • 68 institutional investors held Matinas BioPharma (MTNB) as of Q1 2020, up from 64 in Q4 2019.
  • Funds reported $34.4M of Matinas BioPharma stock for Q1 2020, down 49% quarter-over-quarter.
  • 14 funds opened new Matinas BioPharma positions in Q1 2020 and 8 closed out, a net change of +6 holders.
  • The largest Matinas BioPharma buyer in Q1 2020 was Vivo Capital, an estimated $13.6M added.
  • The largest Matinas BioPharma seller in Q1 2020 was CIBC Private Wealth Group, an estimated $454K sold.

Based on aggregated 13F filings for Q1 2020.